- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03090503
Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up (PAFIP3_3Y)
Open Flexible-dose Randomized Study of the Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: A 3-year Follow-up
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
At present there is no evidence of which antipsychotic treatment would be the choice for treating the appearance of a non-affective psychotic disorder. There are a number of second-generation antipsychotic drugs that have proven effective in controlling positive symptoms of the disease but carry a number of variable side effects so there is no evidence on the treatment of choice in the market. Few studies try to assess the adhesion of a first episode of psychosis as prolonged treatment in time. Thus the development of experimental studies comparing the effectiveness of such treatments in clinical practice is of high interest for clinical psychiatrists.
Study setting and financial support: data for the present investigation are being obtained from an ongoing epidemiological and three-year longitudinal intervention program of first-episode psychosis (PAFIP) conducted at the outpatient clinic and the inpatient unit at the University Hospital Marqués de Valdecilla, Spain. Conforming to international standards for research ethics, this program was approved by the local institutional review board. Patients meeting inclusion criteria and their families provide written informed consent to be included in the PAFIP. The Mental Health Services of Cantabria provided funding for implementing the program. None pharmaceutical company supplied any financial support to it.
Study design: this is a flexible-dose study of two neuroleptics (Aripiprazole and Risperidone) assigned at aleatory ratio 1:1. Rapid titration schedule (5-day), until optimal dose is reached, is a rule used unless severe side effects occur. At the treating physician's discretion, the dose and type of antipsychotic medication could be changed based on clinical efficacy and the profile of side effects during the follow-up period. Antimuscarinic medication, Lormetazepam and Clonazepam are allowed for clinical reasons. No antimuscarinic agents are administered prophylactically. Antidepressants (Sertraline) and mood stabilizers (lithium) are permitted if clinically needed.
Clinical assessment: the severity scale of the Clinical Global Impression (CGI) scale, the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Positive symptoms (SAPS) and the Scale for the Assessment of Negative symptoms (SANS) are used to evaluate symptomatology. To assess general adverse event experiences the Scale of the Udvalg for Kliniske Undersogelser (UKU), the Simpson-Angus Rating Scale (SARS) and the Barnes Akathisia Scale (BAS) are used. The same trained psychiatrist (BC-F) completed all clinical assessments.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Cantabria
-
Santander, Cantabria, Spain, 39008
- University Hospital Marqués de Valdecilla
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Experiencing their first episode of psychosis (First Episode of Psychosis is defined as that psychopathological state in which for the first time and regardless of its duration, the patient has enough severe psychotic symptoms to allow a diagnosis of psychosis, having received no specific psychiatric treatment for him).
- Living in the catchment area (Cantabria).
- No prior treatment with antipsychotic medication or, if previously treated, a total life time of adequate antipsychotic treatment of less than 6 weeks.
- Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for brief psychotic disorder, schizophreniform disorder, schizophrenia, or schizoaffective disorder.
Exclusion Criteria:
- Meeting DSM-IV criteria for drug dependence.
- Meeting DSM-IV criteria for mental retardation.
- Having a history of neurological disease or head injury with loss of consciousness.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Aripiprazole
Oral, dose range 10-30 mg/day, once or twice a day during study duration.
|
Initial dose: 10 mg.
Other Names:
|
Active Comparator: Risperidone
Oral, dose range 1-6 mg/day, once or twice a day during study duration.
|
Initial dose: 2 mg.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness of Aripiprazole and Risperidone at long term as measured by Percentage of discontinuation
Time Frame: 3 years
|
Percentage of discontinuation of the initially assigned treatment: patients who completed the 3 year follow-up assessment and changed initial antipsychotic.
Four reasons for the discontinuation are recorded: 1.- insufficient efficacy; 2.- marked side-effects; 3.- patient reported non-adherence and 4.- other causes.
If more than one reason for discontinuation is present, the most important reason according to the above ranking is selected.
Antipsychotic treatment data (doses, discontinuation and concomitant medications) are registered every 6 months.
Insufficient efficacy is established at the treating physician's judgment only after at least three weeks of treatment.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in general psychopathology measured by BPRS at long term
Time Frame: 3 years
|
Measured by changes in total score of the Brief Psychiatric Rating Scale (BPRS).
|
3 years
|
Change in overall clinical status measured by CGI at long term
Time Frame: 3 years
|
Measured by changes in total score of the Clinical Global Impression (CGI).
|
3 years
|
Change in negative symptoms measured by SANS at long term
Time Frame: 3 years
|
Measured by changes in total score of the Scale for the Assessment of Negative Symptoms (SANS).
|
3 years
|
Change in positive symptoms measured by SAPS at long term
Time Frame: 3 years
|
Measured by changes in total score of the Scale for the Assessment of Positive Symptoms (SAPS).
|
3 years
|
Emergence of adverse events by using the Scale of the Udvalg for Kliniske Undersogelser (UKU)
Time Frame: 3 years
|
Measured by UKU.
Those treatment-emergent adverse events that occurred at a rate of at least 10% in either treatment group are considered.
|
3 years
|
Emergence of akathisia by using the Barnes Akathisia Scale (BAS)
Time Frame: 3 years
|
Measured by BAS.
Treatment-emergent akathisia is assessed by both baseline-to-end changes and newly emergent categorical changes.
|
3 years
|
Emergence of extrapyramidal symptoms by using the Simpson-Angus Rating Scale (SARS)
Time Frame: 3 years
|
Measured by SARS.
Extrapyramidal symptoms is assessed by both baseline-to-end changes and newly emergent categorical changes.
|
3 years
|
Remission rate at long term
Time Frame: 3 years
|
Remission is defined according to Andreasen et al. (2005) criteria covering BPRS and SANS scores: 1.- a score of mild or less (≤3) on six predefined BPRS symptom items: grandiosity, suspiciousness, unusual thought content, hallucinations, conceptual disorganization and mannerisms; and 2.- SANS items scores of ≤2 simultaneously in all items.
These criteria are required to be maintained for at least 6 months.
|
3 years
|
Relapse rate at long term
Time Frame: 3 years
|
Among patients who achieved clinical improvement and stability (CGI rating ≤ 4 and a decrease of at least 30% on BPRS total score and all BPRS key symptom items, by being rated ≤ 3 for more than 4 consecutive weeks at some point during the first 6 months following program entry), relapse is defined as any of the following criteria that occurred during follow-up: 1 - a rating of either 5 or above on any key BPRS symptom items, 2 - CGI rating of ≥ 6 and a change score of CGI of "much worse" or "very much worse", 3 - hospitalization for psychotic psychopathology, or 4 - completed suicide.
The key BPRS symptoms are unusual thought content, hallucinations, suspiciousness, conceptual disorganization and bizarre behaviour.
Exacerbation is defined as any 2-point increase of any of the key BPRS symptoms, excluding changes in which the rating remained at the non-psychotic level (i.e., <3).
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Benedicto Crespo-Facorro, Professor, University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, CIBERSAM Centro Investigación Biomédica en Red Salud Mental, Santander, Spain.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Psychotic Disorders
- Mental Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agonists
- Dopamine Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Aripiprazole
- Risperidone
Other Study ID Numbers
- ROAC2014_3Y
- 2013-005399-16 (EudraCT Number)
- 14-0312 (Other Identifier: AEMPS)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychotic Disorders
-
Medical College of WisconsinCompletedSchizophrenia | Affective Disorders | Psychotic Disorder | Psychotic Mood Disorder
-
Søren Dinesen ØstergaardCompletedAffective Disorders, PsychoticDenmark
-
VA Office of Research and DevelopmentRecruitingMI-CBTech: A Mobile Intervention for Community Integration in Homeless-Experienced Veterans With SMIHomelessness | Schizophrenia Spectrum Disorders | Psychotic Mood Disorders | Psychotic Affective Disorders | Ill-Housed PersonsUnited States
-
Instituto de Investigación Hospital Universitario...Carlos III Health Institute; European Regional Development FundCompletedSchizophrenia and Disorders With Psychotic Features | Psychotic EpisodeSpain
-
Instituto de Investigación Hospital Universitario...CompletedSchizophrenia and Disorders With Psychotic Feature | Psychotic EpisodeSpain
-
Centre hospitalier de Ville-Evrard, FranceRecruiting
-
University Hospital, CaenRecruiting
-
University of California, San DiegoActive, not recruitingSchizophrenia | Schizoaffective Disorder | Mood Disorder, PsychoticUnited States
-
University of MinnesotaUniversity of California, San FranciscoCompletedPsychotic Disorders | Schizophrenia | Schizoaffective Disorder | Cognitive Impairment | Psychosis | Treatment | Psychotic Depression | Psychotic Episode | Active Control | Psychotic Mood DisordersUnited States
-
Boston Medical CenterNational Institute of Mental Health (NIMH); Beth Israel Deaconess Medical CenterCompletedPsychotic Disorders | Psychosis | Psychotic EpisodeUnited States
Clinical Trials on Aripiprazole
-
National Institute on Alcohol Abuse and Alcoholism...Brown UniversityCompleted
-
Otsuka Beijing Research InstituteCompleted
-
H. Lundbeck A/SOtsuka Pharmaceutical Co., Ltd.CompletedSchizophreniaUnited States
-
University of California, Los AngelesAlkermes, Inc.TerminatedSchizophrenia | Schizophreniform Disorder | Schizoaffective Disorder, Depressive TypeUnited States
-
Otsuka Pharmaceutical Co., Ltd.CompletedMajor Depressive DisorderJapan
-
Veterans Medical Research FoundationBristol-Myers SquibbCompleted
-
Otsuka Pharmaceutical Co., Ltd.CompletedSchizophreniaJapan
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaKorea, Republic of, United States, Estonia, Italy, Hungary, Bulgaria, Croatia, France, Poland, Thailand, Puerto Rico, Chile, South Africa, Austria, Belgium
-
Alkermes, Inc.CompletedSchizophreniaUnited States
-
Alkermes, Inc.CompletedSchizophreniaUnited States